| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥269.6B | ¥266.5B | +1.2% |
| Operating Income | ¥35.8B | ¥33.3B | +7.4% |
| Ordinary Income | ¥34.7B | ¥33.5B | +3.6% |
| Net Income | ¥24.0B | ¥27.1B | -11.4% |
| ROE | 5.3% | 6.0% | - |
FY2026 Q3 cumulative results for Stella Chemifa Corporation showed revenue of 269.6 billion yen (YoY +1.2%), operating income of 35.8 billion yen (YoY +7.4%), ordinary income of 34.7 billion yen (YoY +3.6%), and net income of 24.0 billion yen (YoY -11.4%). While top-line growth remained modest at 1.2%, operating profitability improved with operating margin expanding to 13.3% from 12.5% in the prior year period. However, net income declined significantly by 11.4% despite the operating income increase, indicating pressure from non-operating factors and tax burden. The company maintained a strong balance sheet with total assets of 607.2 billion yen, equity of 451.3 billion yen, and an equity ratio of 74.3%, reflecting solid financial health. Cash and deposits of 153.6 billion yen provide substantial liquidity coverage against short-term debt of 17.0 billion yen, yielding a coverage ratio of 9.0x.
Revenue grew modestly by 1.2% YoY to 269.6 billion yen, primarily driven by the High Purity Chemical segment which generated external sales of 23.3 billion yen, up from 23.1 billion yen in the prior year period. The Transportation segment contributed external sales of 3.6 billion yen, increasing from 3.5 billion yen YoY. The High Purity Chemical segment, representing the core business, demonstrated resilience with stable demand fundamentals. Other segments including insurance agency and automobile maintenance businesses contributed 0.1 billion yen to external sales.
On the profit side, gross profit improved to 64.0 billion yen with gross margin expanding to 23.7% from 23.4% YoY, indicating improved product mix or cost efficiency. Operating income increased 7.4% to 35.8 billion yen, with operating margin improving 0.8 percentage points to 13.3%. Selling, general and administrative expenses of 28.2 billion yen were well-controlled, declining slightly from 28.9 billion yen in the prior period. However, ordinary income grew at a slower pace of 3.6% to 34.7 billion yen, suggesting non-operating expenses partially offset operating gains. The gap between operating income and ordinary income widened to 1.1 billion yen from 0.2 billion yen negative in the prior year, primarily due to interest expenses of 0.5 billion yen partially offset by interest income of 0.5 billion yen.
The significant divergence occurred below the ordinary income line, where net income declined 11.4% to 24.0 billion yen. This 10.7 billion yen decrease from ordinary income to net income represents a 30.6% effective tax rate, higher than typical corporate tax rates, suggesting potential one-time tax items or adjustments. The comprehensive income of 21.2 billion yen, down from 29.9 billion yen YoY, reflected the net income decline plus other comprehensive losses.
This represents a revenue up, profit mixed pattern, where operating profitability improved but bottom-line profit declined due to tax and other below-the-line factors.
The High Purity Chemical segment represents the core business, generating revenue of 23.3 billion yen and operating income of 2.9 billion yen in Q3. This segment improved its operating income by 6.4% from 2.7 billion yen in the prior year period, with operating margin of approximately 12.5%. The Transportation segment produced revenue of 6.3 billion yen with operating income of 0.7 billion yen, representing an operating margin of approximately 10.5%. Transportation segment operating income increased significantly by 11.2% from 0.6 billion yen YoY, indicating improved operational efficiency. The High Purity Chemical segment accounts for approximately 87% of total segment sales and 81% of segment operating income, confirming its position as the dominant profit contributor. Other businesses including insurance agency and automobile maintenance contributed 0.3 billion yen in revenue and 0.02 billion yen in operating income. The margin differential between segments shows High Purity Chemical achieving a 2 percentage point premium over Transportation, reflecting the value-added nature of specialized chemical manufacturing.
[Profitability] ROE of 5.3% declined from 6.0% in the prior year period, driven by the net income contraction despite stable equity base. ROA of 4.0% similarly decreased from 4.5% YoY. Operating margin of 13.3% improved 0.8 percentage points from 12.5%, demonstrating enhanced operational efficiency at the EBIT level. Net profit margin of 8.9% contracted from 10.2% YoY, reflecting the tax and non-operating burden that compressed bottom-line profitability. EBIT margin of 13.3% positions the company favorably relative to typical manufacturing sector margins. [Cash Quality] Cash and cash equivalents of 153.6 billion yen provide 9.0x coverage of short-term debt of 17.0 billion yen, indicating substantial liquidity cushion. Current ratio of 347.7% and quick ratio of 318.8% both reflect exceptional short-term solvency. [Investment Efficiency] Total asset turnover of 0.44x declined slightly from 0.45x, suggesting modest pressure on asset utilization efficiency. Inventory turnover period of 100 days extended from prior levels, indicating slower inventory movement. Receivables turnover period of 108 days also lengthened, reflecting extended collection cycles. The cash conversion cycle of 179 days deteriorated, warranting attention to working capital management. [Financial Health] Equity ratio of 74.3% remains robust and increased from 74.1% YoY, providing substantial financial stability. Debt-to-equity ratio of 0.11 for interest-bearing debt reflects conservative leverage with total interest-bearing debt of 48.4 billion yen against equity of 451.3 billion yen. Interest coverage ratio of approximately 66x demonstrates negligible financial burden from debt service. Long-term debt increased 29.6% to 31.4 billion yen from 24.2 billion yen, likely funding the 53.9 billion yen construction in progress shown on the balance sheet.
Cash and deposits increased 13.6 billion yen YoY to 153.6 billion yen, reflecting continued cash accumulation capacity. Operating profit growth contributed to cash generation, though the net income decline of 11.4% suggests some pressure on earnings-based cash flow. Working capital movements show mixed signals with accounts receivable increasing to 80.0 billion yen from 71.2 billion yen, indicating extended collection periods that absorbed cash. Inventory rose to 24.5 billion yen from 23.3 billion yen, further tying up working capital. Accounts payable increased to 29.3 billion yen from 25.1 billion yen, providing 4.2 billion yen of supplier credit that partially offset working capital consumption. The deterioration in receivables and inventory turnover metrics suggests operating cash conversion efficiency declined despite operating profit growth. Long-term borrowings increased 7.2 billion yen to 31.4 billion yen, representing financing activity likely directed toward the substantial construction in progress of 53.9 billion yen, indicating ongoing capital investment projects. The company maintains adequate liquidity with cash covering 9.0x short-term debt and current ratio of 347.7%, though the working capital efficiency deterioration of DSO extending to 108 days and DIO to 100 days warrants management attention.
Ordinary income of 34.7 billion yen versus operating income of 35.8 billion yen shows non-operating net expenses of approximately 1.1 billion yen. This comprises primarily interest income of 0.5 billion yen offset by interest expenses of 0.5 billion yen, with minimal net financial impact. Non-operating income represents less than 0.2% of revenue, indicating earnings are predominantly driven by core operations. The 10.7 billion yen gap between ordinary income and net income reflects an effective tax rate of 30.6%, somewhat elevated and potentially including one-time tax adjustments. No impairment losses or material extraordinary items were disclosed in the segment notes, suggesting the earnings decline stems from tax factors rather than asset write-downs. The working capital deterioration with DSO extending to 108 days and DIO to 100 days raises concerns about earnings quality, as operating profit growth is not being matched by cash conversion. While comprehensive cash flow data is not available in the quarterly disclosure, the balance sheet changes showing receivables and inventory increases exceeding the pace of revenue growth suggests operating cash flow may be lagging reported earnings. The substantial cash position of 153.6 billion yen provides a buffer, but the cash conversion cycle extension to 179 days indicates room for improvement in converting accrual-based profits to actual cash.
The company provides full-year guidance of revenue 360.0 billion yen, operating income 41.0 billion yen, ordinary income 39.0 billion yen, and net income 27.0 billion yen. Against Q3 cumulative results of 269.6 billion yen revenue, the progress rate stands at 74.9%, which is slightly below the standard 75.0% expectation for Q3. Operating income progress of 87.3% significantly exceeds the 75.0% standard, suggesting conservative full-year guidance or potential Q4 cost pressures anticipated by management. Ordinary income progress of 89.0% and net income progress of 89.3% similarly exceed standard pacing. The full-year guidance implies YoY changes of revenue -0.8%, operating income -5.5%, and ordinary income -6.3%, indicating management expects some moderation in FY2026 versus FY2025. Given the strong Q3 progress rates, the company appears on track to meet or potentially exceed the conservative full-year targets, particularly for operating and ordinary income. The guidance assumes dividend per share of 85 yen, consistent with the interim payment already executed.
Annual dividend of 170 yen per share comprises an interim dividend of 85 yen and expected year-end dividend of 85 yen. This represents a payout ratio of approximately 91.5% based on the Q3 cumulative net income of 24.0 billion yen and shares outstanding of approximately 118 million. The payout ratio significantly exceeds typical sustainable levels for manufacturing companies, which generally maintain ratios below 60%. Against full-year net income guidance of 27.0 billion yen, the implied payout ratio would be approximately 74.3%, still elevated but more sustainable. The company's substantial cash reserves of 153.6 billion yen and strong current ratio of 347.7% provide capacity to support the dividend in the near term. However, the combination of high payout ratio and deteriorating working capital efficiency raises questions about long-term dividend sustainability if earnings face pressure. No share buyback programs were disclosed in the available data. The high payout ratio limits retained earnings available for growth investment or balance sheet reinforcement, constraining strategic financial flexibility.
Working capital deterioration represents a key operational risk, with DSO extending to 108 days, DIO to 100 days, and cash conversion cycle reaching 179 days. This indicates slowing collections and inventory turnover that could pressure liquidity if trends continue. The extended working capital cycle absorbs cash that could otherwise be deployed for growth or returned to shareholders.
Business concentration risk stems from heavy reliance on the High Purity Chemical segment, which accounts for 87% of segment revenue and 81% of segment operating income. Demand fluctuations or customer concentration within this segment could significantly impact overall financial performance. The segment notes do not provide customer concentration details, but the specialized nature of high purity chemicals suggests potential exposure to semiconductor or pharmaceutical industry cycles.
Dividend sustainability risk arises from the 91.5% payout ratio based on Q3 results, which exceeds prudent levels for manufacturing companies. While the company maintains strong cash reserves, the net income decline of 11.4% YoY combined with high payout ratio creates vulnerability if earnings face further pressure. This limits financial flexibility for investment or balance sheet management.
[Industry Position] (Reference - Proprietary Analysis) Profitability metrics show Stella Chemifa's ROE of 5.3% aligns closely with the manufacturing industry median of 5.8% for 2025-Q3, positioning the company within the interquartile range of 3.1% to 8.4%. Operating margin of 13.3% exceeds the industry median of 8.9% by 4.4 percentage points, ranking in the upper quartile above the 12.7% threshold, indicating superior operational efficiency. Net profit margin of 8.9% significantly outperforms the industry median of 6.5%, placing the company well above the 9.4% upper quartile benchmark. Financial health indicators demonstrate Stella Chemifa's equity ratio of 74.3% substantially exceeds the industry median of 63.8%, positioning in the top quartile above 74.8%, reflecting conservative capitalization and financial stability. Current ratio of 347.7% far surpasses the industry median of 2.87x, indicating exceptional liquidity management. Efficiency metrics show mixed performance, with asset turnover of 0.44x trailing the industry median of 0.56x, suggesting room for improvement in asset utilization. Operating working capital turnover of 179 days significantly lags the industry median of 111.5 days, confirming the working capital efficiency concerns are relative underperformance versus sector peers. Receivables turnover of 108 days exceeds the industry median of 85.4 days, while inventory turnover of 100 days performs better than the median of 112.3 days but has deteriorated from prior periods. Growth metrics reveal revenue growth of 1.2% trails the industry median of 2.8%, indicating below-average top-line momentum. Overall, Stella Chemifa demonstrates strong profitability and financial stability relative to manufacturing peers, but faces challenges in asset efficiency and working capital management that constrain overall returns. (Industry: Manufacturing, N=105 companies, Comparison: 2025-Q3 period, Source: Proprietary analysis)
Operating profitability demonstrates resilience with operating margin expanding to 13.3% from 12.5% YoY, significantly exceeding the manufacturing industry median of 8.9%. The High Purity Chemical segment, representing 87% of segment revenue, maintains stable demand and improved operating income by 6.4%, confirming the core business fundamentals remain sound. This operational strength positions the company favorably within its sector.
Balance sheet strength provides substantial financial flexibility with equity ratio of 74.3%, cash reserves of 153.6 billion yen, and current ratio of 347.7%, all significantly exceeding industry benchmarks. The conservative capital structure with debt-to-equity ratio of 0.11 and interest coverage of 66x eliminates near-term solvency concerns. However, the 29.6% increase in long-term debt to 31.4 billion yen, likely funding 53.9 billion yen of construction in progress, indicates capital deployment toward capacity expansion that warrants monitoring for return generation.
Working capital management emerges as a critical monitoring area, with cash conversion cycle deteriorating to 179 days versus industry median of 111.5 days, driven by DSO extending to 108 days and inventory turnover slowing. This efficiency lag, combined with net income declining 11.4% despite operating income growth of 7.4%, suggests earnings quality concerns. The 91.5% payout ratio based on Q3 results, though supported by strong cash reserves, constrains financial flexibility for both growth investment and cushion against earnings volatility. Management's ability to improve working capital efficiency and sustain bottom-line profitability will be key factors for maintaining the current shareholder return policy.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.